Novo Nordisk's net profit increased by 8% in 2020 Novo Nordisk A/S Financial report for the period 1 January 2020 to 31 December 2020 Sales increased by 4% in Danish kroner and by 7% at CER to DKK 126.9 billion. Sales in International Operations increased by 7% in Danish kroner (10% at CER), and sales in North America Operations increased by 1% in Danish kroner (3% at CER). Sales growth was negatively impacted by COVID-19, driven by fewer patients initiating treatment. Sales within Diabetes and Obesity care increased by 5% to DKK 108.0 billion (8% at CER), driven by GLP-1 growth of 26% in Danish kroner (29% at CER) reflecting the uptake of Ozempic ® and Rybelsus ®. Biopharm sales decreased by 1% in Danish kroner (increased by 1% at CER).